Ornskov OK With Cinryze 'Cannibalization' As Shire Buys Dyax (And Keeps Baxalta Guessing)
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire is to acquire Dyax for $37.30 in cash per Dyax share, valuing the US biotech at around $5.9bn up front.